<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768013</url>
  </required_header>
  <id_info>
    <org_study_id>MCB 0904</org_study_id>
    <nct_id>NCT01768013</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <brief_summary>
    <textblock>
      The pharmacokinetics of LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate) in
      Japanese subjects with extensive psoriasis vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Betamethasone Dipropionate</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Betamethasone Dipropionate</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Betamethasone Dipropionate</measure>
    <time_frame>Day 14</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Betamethasone Dipropionate</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Betamethasone Dipropionate</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Betamethasone Dipropionate</measure>
    <time_frame>Day 14</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Betamethasone 17-propionate</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Betamethasone 17-propionate</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Betamethasone 17-propionate</measure>
    <time_frame>Day 14</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Betamethasone 17-propionate</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Betamethasone 17-propionate</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Betamethasone 17-propionate</measure>
    <time_frame>Day 14</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Calcipotriol</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Calcipotriol</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of Calcipotriol</measure>
    <time_frame>Day 14</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Calcipotriol</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Calcipotriol</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of Calcipotriol</measure>
    <time_frame>Day 14</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of MC1080</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of MC1080</measure>
    <time_frame>Day 7</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax of MC1080</measure>
    <time_frame>Day 14</time_frame>
    <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of MC1080</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of MC1080.</measure>
    <time_frame>Day 7</time_frame>
    <description>To assess the The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUClast of MC1080.</measure>
    <time_frame>Day 14</time_frame>
    <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage Change in m-PASI From Baseline to Day 28</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is based on the investigator's assessment of the disease.
The extent and severity of redness, thickness and scaliness of psoriasis are recorded for three regions (arms, trunk and legs) and these are used to calculate PASI. The PASI can range between 0 (best) to 64.8 (worst). m-PASI indicate that the scale is modified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Subjects With 'Clear' or 'Almost Clear' Disease by Investigator's Global Assessment at Day 28.</measure>
    <time_frame>Day 28</time_frame>
    <description>Subjects with 'clear' or 'almost clear' disease by investigator's globala ssessment at day 28.
Investigator global assessment (IGA) is based on the investigator's assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear,Almost clear, Mild,Moderate, Severe, and Very severe). The assessment represents the average lesion severity on the trunk and limbs. IGA can range between 1 (best) and 6 (worst). The assessment is based on the condition of the disease at the time of evaluation, and not in relation to the condition at a previous visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 90105 Ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90105</intervention_name>
    <description>Once daily for four weeks</description>
    <arm_group_label>LEO 90105 Ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese subjects having understood and signed a written informed consent form prior
             to any study related procedures being carried out (including activities related to the
             wash out period)

          -  20 years of age or above.

          -  Either sex.

          -  Clinical diagnosis of psoriasis vulgaris amenable to topical treatment involving arms
             and/or trunk and/or legs.

          -  Psoriasis vulgaris on the trunk/limbs (excluding psoriasis on the genitals/skin folds)
             of not more than 30% body surface area (BSA)

          -  An Investigator's global assessment of disease severity (IGA) on area(s) to be treated
             of moderate, severe or very severe and a m-PASI score of â‰¥12.

          -  Females of childbearing potential must have a negative result for a urine pregnancy
             test at Day 1 (Visit 1) and must agree to use an adequate method of birth control, as
             judged by the (sub)investigator, during the study. The contraceptive method should
             have started an adequate amount of time before the pregnancy test, which is dependent
             on the particular method used and as judged by the (sub)investigator, and must
             continue for at least 1 week after the last application of study medication. A female
             is defined as not of child-bearing potential if she is postmenopausal (12 months with
             no menses without an alter-native medical cause) or surgically sterile (tubal ligation
             /section, hysterectomy or bilateral ovariectomy).

        Exclusion Criteria:

          -  Systemic use of biological treatments with a potential effect on psoriasis vulgaris
             within the following time periods prior to Visit 1:

          -  etanercept, adalimumab, infliximab -3 months.

          -  ustekinumab - 4 months

          -  other products - within 3 months/5 half-lives (whichever is longer).

          -  Systemic treatments with all therapies other than biological treatments with a
             potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues,
             retinoids, immu-nosuppressants such as ciclosporin and methotrexate) within 4 weeks
             prior to Visit 1 (use of inhaled and nasal corticosteroids is allowed, use of systemic
             antihistamines is allowed).

          -  Topical treatment of scalp psoriasis with vitamin D analogues (e.g. calcipotriol,
             tacalcitol, maxacalcitol), or very potent WHO group IV corticosteroids within 2 weeks
             prior to Visit 1.

          -  PUVA therapy, UVB therapy or UVA therapy within 4 weeks prior to Visit 1.

          -  Topical treatment of psoriasis on the face, genitals or skin folds with vitamin D
             analogues (e.g. calcipotriol, tacalcitol, maxacalcitol), or potent or very potent WHO
             group III or IV corticosteroids within 2 weeks prior to Visit 1.

          -  Topical treatment of psoriasis on area(s) to be treated with study medication within
             the 2-week period prior to Visit 1. (Use of emollients is allowed during this 2- week
             period, but not during the study.)

          -  Planned initiation of, or changes in, concomitant medication that may affect psoriasis
             vulgaris (e.g., beta-blockers, antimalaria drugs, lithium and ACE inhibitors) during
             the study.

          -  Topical treatment of conditions other than psoriasis with vitamin D analogues (e.g.
             calcipotriol, tacalcitol, maxacalcitol), or potent or very potent WHO group III or IV
             corti-costeroids within 2 weeks prior to Visit 1.

          -  Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis.

          -  Clinical signs or symptoms of Cushing's disease or Addison's disease

          -  Patients with any of the following disorders (a) or symptoms (b) present on the
             area(s) to be treated with study medication: (a) viral (e.g., herpes or varicella)
             lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin
             manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris,
             atrophic skin, striae atrophicae, ichthyosis, acne rosacea, ulcers, burns, frostbite,
             wounds, or (b) fragility of skin veins.

          -  Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and
             cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris.

          -  Planned excessive exposure of treated areas(s) to either natural or artificial
             sunlight (including tanning boths, sun lamps, etc) during the study.

          -  Known or suspected disorders of calcium metabolism associated with hypercalcaemia
             (subjects with results for albumin-corrected serum calcium above the reference range
             from the sample taken at the Washout/Screening Visit.

          -  Severe renal insufficiency, severe hepatic disorders or severe heart disease.

          -  Known or suspected hypersensitivity to components of the investigational products.

          -  Current participation in any other interventional clinical study

          -  Subjects who have received treatment with any non-marketed drug substance (i.e. an
             agent which has not yet been made available for clinical use following registration)
             within the 4-week period prior to Visit 1 or longer, if the class of substance
             re-quires a longer washout as defined above (e.g. biological treatments).

          -  Females who are pregnant, wishing to become pregnant during the study, or are
             breast-feeding

          -  Patients suspected of being unable to comply with the study protocol, e.g. due to
             alcoholism, drug dependence or psychotic state.

          -  Previous enrollment in this study.

          -  Hospitalised patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <results_first_submitted>November 8, 2013</results_first_submitted>
  <results_first_submitted_qc>November 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2013</results_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject first visit: 09-Jul-2012 Last subject last visit: 30-Oct-2012</recruitment_details>
      <pre_assignment_details>Prior to treatment at Visit 1, a washout period was completed if the subject was treated or had recently been treated with anti-psoriatic treatments or other relevant medication, as defined by the exclusion criteria. The washout period could last up to a maximum of 4 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LEO 90105 Ointment</title>
          <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LEO 90105 Ointment</title>
          <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Betamethasone Dipropionate</title>
        <description>The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Betamethasone Dipropionate</title>
          <description>The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Betamethasone Dipropionate</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Betamethasone Dipropionate</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Betamethasone Dipropionate</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Betamethasone Dipropionate</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Betamethasone Dipropionate</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Betamethasone Dipropionate</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Betamethasone Dipropionate</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Betamethasone Dipropionate</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Betamethasone Dipropionate</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Betamethasone Dipropionate</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Betamethasone 17-propionate</title>
        <description>The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Betamethasone 17-propionate</title>
          <description>The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.8" spread="351.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Betamethasone 17-propionate</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Betamethasone 17-propionate</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.5" spread="77.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Betamethasone 17-propionate</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Betamethasone 17-propionate</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" spread="64.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Betamethasone 17-propionate</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Betamethasone 17-propionate</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1036.7" spread="1885.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Betamethasone 17-propionate</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Betamethasone 17-propionate</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="570.92" spread="517.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Betamethasone 17-propionate</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Betamethasone 17-propionate</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="634.65" spread="467.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Calcipotriol</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Calcipotriol</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.6">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Calcipotriol</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Calcipotriol</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of Calcipotriol</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of Calcipotriol</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Calcipotriol</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Calcipotriol</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.6">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Calcipotriol</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Calcipotriol</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of Calcipotriol</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of Calcipotriol</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of MC1080</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of MC1080</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.35">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of MC1080</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of MC1080</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.57" spread="36.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: Cmax of MC1080</title>
        <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: Cmax of MC1080</title>
          <description>The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of MC1080</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of MC1080</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.9">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of MC1080.</title>
        <description>To assess the The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of MC1080.</title>
          <description>To assess the The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.2" spread="175.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic: AUClast of MC1080.</title>
        <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic: AUClast of MC1080.</title>
          <description>The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined</description>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The pharmacokinetic parameter could not be reliably estimated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage Change in m-PASI From Baseline to Day 28</title>
        <description>Psoriasis Area and Severity Index (PASI) is based on the investigator's assessment of the disease.
The extent and severity of redness, thickness and scaliness of psoriasis are recorded for three regions (arms, trunk and legs) and these are used to calculate PASI. The PASI can range between 0 (best) to 64.8 (worst). m-PASI indicate that the scale is modified.</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage Change in m-PASI From Baseline to Day 28</title>
          <description>Psoriasis Area and Severity Index (PASI) is based on the investigator's assessment of the disease.
The extent and severity of redness, thickness and scaliness of psoriasis are recorded for three regions (arms, trunk and legs) and these are used to calculate PASI. The PASI can range between 0 (best) to 64.8 (worst). m-PASI indicate that the scale is modified.</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.4" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Subjects With 'Clear' or 'Almost Clear' Disease by Investigator's Global Assessment at Day 28.</title>
        <description>Subjects with 'clear' or 'almost clear' disease by investigator's globala ssessment at day 28.
Investigator global assessment (IGA) is based on the investigatorâ€™s assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear,Almost clear, Mild,Moderate, Severe, and Very severe). The assessment represents the average lesion severity on the trunk and limbs. IGA can range between 1 (best) and 6 (worst). The assessment is based on the condition of the disease at the time of evaluation, and not in relation to the condition at a previous visit.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 90105 Ointment</title>
            <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Subjects With 'Clear' or 'Almost Clear' Disease by Investigator's Global Assessment at Day 28.</title>
          <description>Subjects with 'clear' or 'almost clear' disease by investigator's globala ssessment at day 28.
Investigator global assessment (IGA) is based on the investigatorâ€™s assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear,Almost clear, Mild,Moderate, Severe, and Very severe). The assessment represents the average lesion severity on the trunk and limbs. IGA can range between 1 (best) and 6 (worst). The assessment is based on the condition of the disease at the time of evaluation, and not in relation to the condition at a previous visit.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LEO 90105 Ointment</title>
          <description>Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical trial disclosure manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>00 45 44 94 58 88</phone>
      <email>ctr.disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

